🔗 Share this article

As America continues making unprecedented revisions to its immunization recommendations, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about COVID-19 shots in the global health crisis and has focused upon potential deaths following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Program

Public health authorities planned to announce sweeping revisions to the pediatric vaccine schedule in December, synchronizing the US with the Danish vaccine program, according to reports – a major change that would put the US at odds with many the global community with insufficient data for benefit. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is scheduled to present at the event. She was just designated interim head of the FDA’s CDER, the fifth person to run the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending certain childhood immunization guidelines in the US in order to be more like the Danish model, a nation with nationalized medicine and a population approximately the population of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Expertise

The appointee has little discernible track record in drug development, oversight or management, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a large organization. She has no expertise in industry regulation.”

Former directors of CBER would “grasp regulatory frameworks and the science of medication creation”, said a former acting FDA commissioner. “Objectively, she lacks the type of experience that former directors who headed CBER have had.”

CDER has an vast range of responsibilities at the agency, Woodcock emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and more, and each of these must be looked after,” she explained. “The thing you overlook, that is the part that I always told people is going to cause problems.”

There is also, a major administrative element to the role, which manages more than 5,000 staff members. “It’s a enormous management job, if you do it right,” the former official added.

Response and Disputed Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this assignment represents increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “inquiries are based on flawed assumptions”.

“Her resume is consistent with the functions of her role,” the representative explained, pointing to the months Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a controversial rapid medication authorization process that reportedly concerned her preceding directors. “By what process are these therapies being chosen for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

In general, he remarked, “the FDA appears to be shifting towards less stringent oversight of all drugs, aside from vaccines.”

Public Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if concerning, past, some experts have noted. She authored a research paper using unverified crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the current government featured altering regulations for new vaccines and ending “non-essential” vaccines, she remarked following the vote on a online show. At the agency, Høeg has according to sources floated the idea of preventing young men from getting COVID-19 vaccines.

“She is an all-around true believer who commences with her conclusions and tailors the evidence to accommodate the science in a extremely disingenuous, fraudulent manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|